COMPOSITIONS USEFUL FOR TREATING IRRITABLE BOWEL SYNDROME
The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof.
1 . A method of treating IBS-c or IBS-a in a human subject in need thereof comprising orally administering to said subject a therapeutically effective amount of a compound represented by the following structure:
or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the therapeutically effective amount ranges from greater than 2.4 mg/per day to about 8.0 mg/day.
2 . The method of claim 1 , wherein the subject suffers from IBS-c.
3 . The method of claim 1 or 2 , wherein the asterisked carbon atom is in the (R) configuration.
4 . The method of claim 3 , wherein the compound is in the form of the monohydrochloride salt.
5 . The method of claim 1 or 2 , wherein the compound is administered in a single dose.
6 . The method of claim 1 or 2 , wherein the compound in administered in multiple dosages.
7 . The method of claim 6 , wherein the compound is administered in equivalent doses twice a day.
8 . The method of claim 6 , wherein the compound is administered in equivalent doses three times a day.
9 . The method of claim 8 , wherein the compound is administered coincident with the breakfast, lunch and dinner meals of the subject.
10 . The method of claim 5 , wherein about 4.2 mg per day is administered.
11 . The method of claim 6 , wherein about 4.2 mg per day is administered.
12 . The method of claim 7 , wherein about 4.2 mg per day is administered.
13 . The method of claim 8 , wherein about 4.2 mg per day is administered.
14 . The method of claim 9 , wherein about 4.2 mg per day is administered.
15 . A method of treating irritable bowel syndrome with constipation (IBS-c) in a human in need of treatment comprising orally administering to the subject a therapeutically effective amount of DDP-733, wherein the therapeutically effective amount is about 4.2 mg/per day.
16 . The method of claim 15 , wherein the about 4.2 mg/day dose is administered in three equivalent doses.
17 . The method of claim 16 , wherein each dose is administered from about 60 minutes to about 30 minutes prior to the breakfast, lunch and dinner of the subject.